SUBSCRIBE
SUBSCRIBE
News   FDA

Daiichi Sankyo Co Ltd., Eli Lilly and Company (JOBS) Win European Approval for Prasugrel

February 23, 2009 | 
1 min read
BOSTON, Feb 23 (Reuters) - Eli Lilly & Co and Japan's Daiichi Sankyo Co said on Monday that they had won European approval for their blood-thinning drug Efient, also known as prasugrel.
FDA Approvals
Eli Lilly and Company Daiichi Sankyo
MORE ON THIS TOPIC
Focus on the path, Businessman running on his own track
Rare diseases
Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug
June 10, 2026
 · 
2 min read
 · 
Tristan Manalac
There is one person missing to complete the team. Recruiting workers. Workforce gaps, job recruitment, and staffing needs. Job vacancy. Talent acquisition campaigns to fill essential roles.
FDA
Busy FDA gives rare disease sector complementary pathways, unanswered questions
June 8, 2026
 · 
8 min read
 · 
Nick Paul Taylor
businessman chooses the path strategy 3d illustration
FDA
Post-Makary, new rare disease framework faces fresh uncertainty
June 8, 2026
 · 
7 min read
 · 
Heather McKenzie
Opinion
The next FDA commissioner must be a champion for gene therapies
June 5, 2026
 · 
4 min read
 · 
Erik Paulsen